The effect of rosiglitazone on ischemia-reperfusion-injury using annexin A5 scintigraphy. A double blind placebo- controlled cross-over study in subjects with the metabolic syndrome
Phase of Trial: Phase II
Latest Information Update: 23 Aug 2010
At a glance
- Drugs Rosiglitazone (Primary)
- Indications Metabolic syndrome
- Focus Pharmacodynamics
- 23 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Aug 2010 Actual end date (Oct 2008) added as reported by ClinicalTrials.gov.
- 15 Jul 2009 Status changed from not yet recruiting to active, no longer recruiting.